Collegium Pharmaceutical (COLL)

• Market cap: $1.09B
• 1 day: -3.78%
• 5 days: -5.7%
• 1 month: -5.64%
• 3 months: -26.29%
• 6 months: 1.2%
• Year to date: -26.18%
• 1 year: 24.39%
• 5 years: 44.43%
• 10 years: 77.27%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Employees: 423